Aurobindo Pharma reported strong Q2FY26 results with revenue reaching ₹8,286 Cr, a 6.3% year-over-year growth. EBITDA stood at ₹1,678 Cr with a margin of 20.3%. Net profit for the quarter was ₹848 Cr. The company also filed 13 ANDAs in the US, receiving approval for 7 products and launching 6.
Key Financial Highlights
Aurobindo Pharma showcased a robust financial performance in Q2FY26:
- Revenue: ₹8,286 Cr, up 6.3% YoY
- EBITDA: ₹1,678 Cr, with a 20.3% margin
- Net Profit: ₹848 Cr
Compared to Q2FY25:
- Revenue: ₹7,796 Cr
- EBITDA: ₹1,566 Cr
- Net Profit: ₹817 Cr
Business Segment Performance
Aurobindo Pharma’s key markets demonstrated varied growth:
- USA: ₹3,638 Cr, a 3.1% increase
- Europe: ₹2,480 Cr, showing strong growth at 17.8%
- Growth Markets: ₹882 Cr, up by 8.7%
- ARV: ₹325 Cr, displaying significant growth of 68.7%
US Formulations Business
The US formulations business saw:
- 2% QoQ increase in revenue
- Accounting for 43.9% of consolidated revenue
- Excluding gRevlimid, revenues grew by 6% QoQ
- Filed 13 ANDAs with USFDA
- 7 ANDAs received approval
- 6 product launches
Biosimilars Update
Aurobindo continues to strengthen its biosimilars portfolio:
- Three biosimilar products approved in the EU
- Ready for regulatory submission of BP16 (Prolia biosimilar) in Europe
- Phase 3 recruitment completed for BP01 (Avastin biosimilar)
Debt and Cash Flow
The company maintains a strong financial position:
- Net cash position (including investments) at approximately US$ 170 million as of September 2025
Source: BSE